Liquidia Corporation
General ticker "LQDA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.6B (TTM average)
Liquidia Corporation follows the US Stock Market performance with the rate: 40.6%.
Estimated limits based on current volatility of 3.2%: low 32.80$, high 36.40$
Factors to consider:
- Total employees count: 216 (+28.6%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: FDA approval delays, Patent infringement claims, Manufacturing issues, Funding shortfall, Labor/talent shortage/retention
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [23.66$, 49.28$]
- 2026-12-31 to 2027-12-31 estimated range: [21.02$, 44.17$]
Financial Metrics affecting the LQDA estimates:
- Positive: with PPE of -42.1 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -1.19 <= 2.37
- Negative: negative Industry operating cash flow (median)
- Negative: 0.75 < Interest expense per share per price, % of 0.80
- Negative: -3.92 < Inventory ratio change, % of -1.69
- Negative: 12.78 < Shareholder equity ratio, % of 13.65 <= 25.20
- Negative: Investing cash flow per share per price, % of -0.21 <= -0.14
- Negative: negative Net income
- Negative: negative Industry operating income (median)
Short-term LQDA quotes
Long-term LQDA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $17.49MM | $14.00MM | $158.32MM |
| Operating Expenses | $90.87MM | $135.29MM | $209.70MM |
| Operating Income | $-73.38MM | $-121.29MM | $-51.38MM |
| Non-Operating Income | $-5.12MM | $-9.10MM | $-17.55MM |
| Interest Expense | $6.27MM | $12.49MM | $24.17MM |
| R&D Expense | $43.24MM | $47.84MM | $39.28MM |
| Income(Loss) | $-78.50MM | $-130.39MM | $-68.92MM |
| Net Income(Loss)* | $-78.50MM | $-130.39MM | $-68.92MM |
| Stockholders Equity | $47.29MM | $77.28MM | $44.75MM |
| Inventory | $0.00MM | $0.24MM | $0.00MM |
| Assets | $118.33MM | $230.31MM | $327.93MM |
| Operating Cash Flow | $-41.56MM | $-93.42MM | $-35.69MM |
| Capital expenditure | $1.29MM | $4.95MM | $4.34MM |
| Investing Cash Flow | $-11.29MM | $-8.44MM | $-6.34MM |
| Financing Cash Flow | $43.25MM | $194.66MM | $59.73MM |
| Earnings Per Share** | $-1.21 | $-1.66 | $-0.80 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.